ROQ
NEUTRALRoquefort Therapeutics Extends Lyramid Sale Deadline
The biotech company extends the deadline to complete the sale of its subsidiary Lyramid to Pleiades Pharma.
Roquefort Therapeutics
1.9000GBX
0.00%
Market Cap
3.04M
Volume
2.27M
130% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
-0.47
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p1.9000p6.7750p
1.9000p
Upcoming Events
Q4 2025
Expected milestone achievement for next licensing revenue
High Impact Event
ROQ
NEUTRALRoquefort Therapeutics Director Increases Stake
The biotech company has announced that its Executive Chairman has purchased additional ordinary shares in the company.
ROQ
NEUTRALRoquefort Therapeutics Director Increases Shareholding
The biotech company has announced that one of its non-executive directors has purchased additional shares in the business.
ROQ
NEUTRALRoquefort Therapeutics Extends Deadline for Lyramid SPA
The biotech company has extended the deadline to complete the sale of its subsidiary Lyramid to Pleiades Pharma.
ROQ
BADRoquefort Therapeutics Announces Equity Issue to Settle Former Employee Claim
The biotech company has issued new shares to settle a former employee's claim, raising concerns about its financial health and management's priorities.
ROQ
NEUTRALRoquefort Therapeutics Announces Annual General Meeting
The biotech company has announced the date and details for its upcoming Annual General Meeting.
ROQ
NEUTRALRoquefort Therapeutics Extends Convertible Loan Note Maturity
The biotech company has agreed with holders of its convertible loan notes to extend the maturity date to the end of 2025.
ROQ
NEUTRALRoquefort Therapeutics Provides Update on Corporate Transactions and Forward Strategy
The biotech company announces plans to sell two subsidiaries and pivot its focus towards acquiring clinical-stage assets or revenue-generating life science businesses.
ROQ
BADRoquefort Therapeutics Reports Annual Results Amid Ongoing Development and Financial Challenges
The pre-clinical biotech firm reported continued losses and declining cash reserves, despite progress in research programs. It's pursuing asset sales and new opportunities to generate short-term value amid funding challenges.